3-dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy

Manickam Muruganandham, Patrick P. Clerkin, Brian J. Smith, Carryn M. Anderson, Ann Morris, Aristides A. Capizzano, Vincent Magnotta, Sarah M. McGuire, Mark C. Smith, John E. Bayouth, John M. Buatti

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose To evaluate the utility of 3-dimensional magnetic resonance (3D-MR) proton spectroscopic imaging for treatment planning and its implications for early response assessment in glioblastoma multiforme. Methods and Materials Eighteen patients with newly diagnosed, histologically confirmed glioblastoma had 3D-MR proton spectroscopic imaging (MRSI) along with T2 and T1 gadolinium-enhanced MR images at simulation and at boost treatment planning after 17 to 20 fractions of radiation therapy. All patients received standard radiation therapy (RT) with concurrent temozolomide followed by adjuvant temozolomide. Imaging for response assessment consisted of MR scans every 2 months. Progression-free survival was defined by the criteria of MacDonald et al. MRSI images obtained at initial simulation were analyzed for choline/N-acetylaspartate ratios (Cho/NAA) on a voxel-by-voxel basis with abnormal activity defined as Cho/NAA ≥2. These images were compared on anatomically matched MRSI data collected after 3 weeks of RT. Changes in Cho/NAA between pretherapy and third-week RT scans were tested using Wilcoxon matched-pairs signed rank tests and correlated with progression-free survival, radiation dose and location of recurrence using Cox proportional hazards regression. Results After a median follow-up time of 8.6 months, 50% of patients had experienced progression based on imaging. Patients with a decreased or stable mean or median Cho/NAA values had less risk of progression (P<.01). Patients with an increase in mean or median Cho/NAA values at the third-week RT scan had a significantly greater chance of early progression (P<.01). An increased Cho/NAA at the third-week MRSI scan carried a hazard ratio of 2.72 (95% confidence interval, 1.10-6.71; P=.03). Most patients received the prescription dose of RT to the Cho/NAA ≥2 volume, where recurrence most often occurred. Conclusion Change in mean and median Cho/NAA detected at 3 weeks was a significant predictor of early progression. The potential impact for risk-adaptive therapy based on early spectroscopic findings is suggested.

Original languageEnglish (US)
Pages (from-to)181-189
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume90
Issue number1
DOIs
StatePublished - Sep 1 2014

Fingerprint

choline
Glioblastoma
Choline
magnetic resonance
radiation therapy
Radiotherapy
Magnetic Resonance Imaging
progressions
temozolomide
Protons
proton magnetic resonance
hazards
Disease-Free Survival
protons
planning
Magnetic Resonance Spectroscopy
rank tests
Recurrence
dosage
N-acetylaspartate

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

3-dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. / Muruganandham, Manickam; Clerkin, Patrick P.; Smith, Brian J.; Anderson, Carryn M.; Morris, Ann; Capizzano, Aristides A.; Magnotta, Vincent; McGuire, Sarah M.; Smith, Mark C.; Bayouth, John E.; Buatti, John M.

In: International Journal of Radiation Oncology Biology Physics, Vol. 90, No. 1, 01.09.2014, p. 181-189.

Research output: Contribution to journalArticle

Muruganandham, M, Clerkin, PP, Smith, BJ, Anderson, CM, Morris, A, Capizzano, AA, Magnotta, V, McGuire, SM, Smith, MC, Bayouth, JE & Buatti, JM 2014, '3-dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy', International Journal of Radiation Oncology Biology Physics, vol. 90, no. 1, pp. 181-189. https://doi.org/10.1016/j.ijrobp.2014.05.014
Muruganandham, Manickam ; Clerkin, Patrick P. ; Smith, Brian J. ; Anderson, Carryn M. ; Morris, Ann ; Capizzano, Aristides A. ; Magnotta, Vincent ; McGuire, Sarah M. ; Smith, Mark C. ; Bayouth, John E. ; Buatti, John M. / 3-dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. In: International Journal of Radiation Oncology Biology Physics. 2014 ; Vol. 90, No. 1. pp. 181-189.
@article{f4485f6198ca41d2b013fbfab6ece19a,
title = "3-dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy",
abstract = "Purpose To evaluate the utility of 3-dimensional magnetic resonance (3D-MR) proton spectroscopic imaging for treatment planning and its implications for early response assessment in glioblastoma multiforme. Methods and Materials Eighteen patients with newly diagnosed, histologically confirmed glioblastoma had 3D-MR proton spectroscopic imaging (MRSI) along with T2 and T1 gadolinium-enhanced MR images at simulation and at boost treatment planning after 17 to 20 fractions of radiation therapy. All patients received standard radiation therapy (RT) with concurrent temozolomide followed by adjuvant temozolomide. Imaging for response assessment consisted of MR scans every 2 months. Progression-free survival was defined by the criteria of MacDonald et al. MRSI images obtained at initial simulation were analyzed for choline/N-acetylaspartate ratios (Cho/NAA) on a voxel-by-voxel basis with abnormal activity defined as Cho/NAA ≥2. These images were compared on anatomically matched MRSI data collected after 3 weeks of RT. Changes in Cho/NAA between pretherapy and third-week RT scans were tested using Wilcoxon matched-pairs signed rank tests and correlated with progression-free survival, radiation dose and location of recurrence using Cox proportional hazards regression. Results After a median follow-up time of 8.6 months, 50{\%} of patients had experienced progression based on imaging. Patients with a decreased or stable mean or median Cho/NAA values had less risk of progression (P<.01). Patients with an increase in mean or median Cho/NAA values at the third-week RT scan had a significantly greater chance of early progression (P<.01). An increased Cho/NAA at the third-week MRSI scan carried a hazard ratio of 2.72 (95{\%} confidence interval, 1.10-6.71; P=.03). Most patients received the prescription dose of RT to the Cho/NAA ≥2 volume, where recurrence most often occurred. Conclusion Change in mean and median Cho/NAA detected at 3 weeks was a significant predictor of early progression. The potential impact for risk-adaptive therapy based on early spectroscopic findings is suggested.",
author = "Manickam Muruganandham and Clerkin, {Patrick P.} and Smith, {Brian J.} and Anderson, {Carryn M.} and Ann Morris and Capizzano, {Aristides A.} and Vincent Magnotta and McGuire, {Sarah M.} and Smith, {Mark C.} and Bayouth, {John E.} and Buatti, {John M.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.ijrobp.2014.05.014",
language = "English (US)",
volume = "90",
pages = "181--189",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - 3-dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy

AU - Muruganandham, Manickam

AU - Clerkin, Patrick P.

AU - Smith, Brian J.

AU - Anderson, Carryn M.

AU - Morris, Ann

AU - Capizzano, Aristides A.

AU - Magnotta, Vincent

AU - McGuire, Sarah M.

AU - Smith, Mark C.

AU - Bayouth, John E.

AU - Buatti, John M.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Purpose To evaluate the utility of 3-dimensional magnetic resonance (3D-MR) proton spectroscopic imaging for treatment planning and its implications for early response assessment in glioblastoma multiforme. Methods and Materials Eighteen patients with newly diagnosed, histologically confirmed glioblastoma had 3D-MR proton spectroscopic imaging (MRSI) along with T2 and T1 gadolinium-enhanced MR images at simulation and at boost treatment planning after 17 to 20 fractions of radiation therapy. All patients received standard radiation therapy (RT) with concurrent temozolomide followed by adjuvant temozolomide. Imaging for response assessment consisted of MR scans every 2 months. Progression-free survival was defined by the criteria of MacDonald et al. MRSI images obtained at initial simulation were analyzed for choline/N-acetylaspartate ratios (Cho/NAA) on a voxel-by-voxel basis with abnormal activity defined as Cho/NAA ≥2. These images were compared on anatomically matched MRSI data collected after 3 weeks of RT. Changes in Cho/NAA between pretherapy and third-week RT scans were tested using Wilcoxon matched-pairs signed rank tests and correlated with progression-free survival, radiation dose and location of recurrence using Cox proportional hazards regression. Results After a median follow-up time of 8.6 months, 50% of patients had experienced progression based on imaging. Patients with a decreased or stable mean or median Cho/NAA values had less risk of progression (P<.01). Patients with an increase in mean or median Cho/NAA values at the third-week RT scan had a significantly greater chance of early progression (P<.01). An increased Cho/NAA at the third-week MRSI scan carried a hazard ratio of 2.72 (95% confidence interval, 1.10-6.71; P=.03). Most patients received the prescription dose of RT to the Cho/NAA ≥2 volume, where recurrence most often occurred. Conclusion Change in mean and median Cho/NAA detected at 3 weeks was a significant predictor of early progression. The potential impact for risk-adaptive therapy based on early spectroscopic findings is suggested.

AB - Purpose To evaluate the utility of 3-dimensional magnetic resonance (3D-MR) proton spectroscopic imaging for treatment planning and its implications for early response assessment in glioblastoma multiforme. Methods and Materials Eighteen patients with newly diagnosed, histologically confirmed glioblastoma had 3D-MR proton spectroscopic imaging (MRSI) along with T2 and T1 gadolinium-enhanced MR images at simulation and at boost treatment planning after 17 to 20 fractions of radiation therapy. All patients received standard radiation therapy (RT) with concurrent temozolomide followed by adjuvant temozolomide. Imaging for response assessment consisted of MR scans every 2 months. Progression-free survival was defined by the criteria of MacDonald et al. MRSI images obtained at initial simulation were analyzed for choline/N-acetylaspartate ratios (Cho/NAA) on a voxel-by-voxel basis with abnormal activity defined as Cho/NAA ≥2. These images were compared on anatomically matched MRSI data collected after 3 weeks of RT. Changes in Cho/NAA between pretherapy and third-week RT scans were tested using Wilcoxon matched-pairs signed rank tests and correlated with progression-free survival, radiation dose and location of recurrence using Cox proportional hazards regression. Results After a median follow-up time of 8.6 months, 50% of patients had experienced progression based on imaging. Patients with a decreased or stable mean or median Cho/NAA values had less risk of progression (P<.01). Patients with an increase in mean or median Cho/NAA values at the third-week RT scan had a significantly greater chance of early progression (P<.01). An increased Cho/NAA at the third-week MRSI scan carried a hazard ratio of 2.72 (95% confidence interval, 1.10-6.71; P=.03). Most patients received the prescription dose of RT to the Cho/NAA ≥2 volume, where recurrence most often occurred. Conclusion Change in mean and median Cho/NAA detected at 3 weeks was a significant predictor of early progression. The potential impact for risk-adaptive therapy based on early spectroscopic findings is suggested.

UR - http://www.scopus.com/inward/record.url?scp=84905902862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905902862&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2014.05.014

DO - 10.1016/j.ijrobp.2014.05.014

M3 - Article

C2 - 24986746

AN - SCOPUS:84905902862

VL - 90

SP - 181

EP - 189

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -